Abstract:Background. A large number of cancer-related deaths in the world can be attributed to liver hepatocellular carcinoma (LIHC). The purpose of this study is to explore protein tyrosine phosphatase type IV A member 3 (PTP4A3/PRL-3) as a new and reliable biomarker to predict the prognosis of LIHC and determine the potential therapeutic targets or drugs that can be used for treating LIHC. Methods. We included three LIHC datasets with clinical information and expression profiles from public databases. The expression level of PTP4A3 was analyzed, and based on the results, the samples were divided into high- and low-expression groups. The Kaplan–Meier survival analysis method was used to determine the relationship between PTP4A3 and prognosis. The enrichment differences among the functional pathways associated with the high- and low-expression groups were determined using the gene set enrichment analysis (GSEA) method. Five methods were used to determine the differences among the tumor microenvironment in the low- and high-expression groups. The sensitivity of the low- and high-expression groups toward different drug treatment methods was predicted by analyzing the Tumor Immune Dysfunction and Exclusion (TIDE) scores and determining the biochemical half-maximal inhibitory concentration (IC50). Results. The expression levels of the LIHC and adjacent samples were analyzed, and it was observed that the expression level of PTP4A3 in tumor tissue was significantly higher than the expression level of the same gene in the adjacent samples. It was also inferred that it might be a cancer-promoting gene. It was concluded that high-expression results in a significantly poor prognosis. The high-expression group was significantly enriched in the tumor-related pathways, such as the PI3K-AKT signaling pathway. In addition, the results obtained by conducting immune infiltration analysis revealed a significant positive correlation between some immune scores and the gene PTP4A3. The drug KIN001−135 and gene PTP4A3 were also found to correlate positively with each other. CP466722, Pyrimethamine, AKT inhibitor VIII, Embelin, Cisplatin, QS11, Bexarotene, and Midostaurin negatively correlated with PTP4A3 associated with the three datasets. Moreover, the drugs Cisplatin, QS11, Midostaurin, and CP466722 were more sensitive toward the high-expression group than the low PTP4A3 expression group. Significant differences were observed in these cases. Conclusion. PTP4A3/PRL-3 is potentially associated with the progression, metastasis, and invasion of LIHC. The prognosis of LIHC patients is negatively impacted by the high-expression levels of the gene. The results indicate that PTP4A3/PRL-3 is an important prognostic factor for LIHC and is a new potential prognostic detection target. The discovery of the 8 drugs that were negatively associated with PTP4A3 provided a new direction that can be developed in the future for the treatment of LIHC.

Correlation Between Phosphatase of Regenerating Liver-3 and Portal Vein Tumor Thrombus of Hepatocellular Carcinoma

Phosphatase of Regenerating Liver-3: a Novel and Promising Marker in Human Endometriosis.

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

Expression of Phosphatase Regenerating Liver 3 is an Independent Prognostic Indicator for Gastric Cancer

Phosphatase Regenerating Liver 3 Participates in Integrinβ1/FAK-Src/MAPK Signaling Pathway and Contributes to the Regulation of Malignant Behaviors in Hepatocellular Carcinoma Cells

Combined DeRitis ratio and alkaline phosphatase on the Prediction of Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma

Prognostic Value of PRL-3 Overexpression in Early Stages of Colonic Cancer.

Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma

Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer

The Association of the Expression Level of Protein Tyrosine Phosphatase Prl-3 Protein with Liver Metastasis and Prognosis of Patients with Colorectal Cancer

Correlation Between Recurrence of Primary Hepatocellular Carcinoma after Liver Transplantation and Expression of CK19 and GPC3

PRR7-AS1 Correlates with Immune Cell Infiltration and is a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Phosphatase of Regenerating Liver-3 (PRL-3) is Associated with Metastasis and Poor Prognosis in Gastric Carcinoma

Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.

Expression and Prognostic Impact of NTF3 and TrkC in Hepatocellular Carcinoma.

The expression of PDGFRα in HCC and association with prognosis

Correlation of serum GP73 level and prognosis of patients with hepatocellular carcinoma after hepatectomy

Urokinase-type plasminogen activator (uPA),hopital uPA receptor (uPA-R) and inhibitors (PA I-1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis

Relationship between preoperative C reactive protein level and prognosis in primary liver cancer patients with liver resection

Expression of PRL-3 Gene in Colorectal Cancer and Its Clinical Significance